A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Required: IDH1 wild-type

Required: IDH2 wild-type

Must have received: radiation therapy — recurrent GBM

at a minimum radiation therapy (RT) [required for recurrent disease]

Cannot have received: prolifeprospan 20 with carmustine wafer (carmustine)

Prior prolifeprospan 20 with carmustine wafer

Cannot have received: intracerebral, intratumoral, or cerebral spinal fluid (CSF) agent

Prior intracerebral, intratumoral, or cerebral spinal fluid (CSF) agent

Cannot have received: radiation therapy for GBM or lower-grade glioma

Prior radiation treatment for GBM or lower-grade glioma [excluded for newly diagnosed]

Cannot have received: chemotherapy for GBM or lower-grade glioma

Prior chemotherapy or immunotherapy for GBM or lower-grade glioma [excluded for newly diagnosed]

Cannot have received: immunotherapy for GBM or lower-grade glioma

Prior chemotherapy or immunotherapy for GBM or lower-grade glioma [excluded for newly diagnosed]

Cannot have received: concurrent active therapy for GBM outside of the trial

Receiving additional, concurrent, active therapy for GBM outside of the trial

Cannot have received: lomustine (lomustine)

any prior treatment with lomustine

Cannot have received: experimental agents (any of the experimental arms)

agents part of any of the experimental arms

Cannot have received: bevacizumab or other VEGF or VEGF receptor-mediated targeted agent (bevacizumab)

bevacizumab or other vascular endothelial growth factor (VEGF) or VEGF receptor-mediated targeted agent